Login to Your Account



Clinic Roundup


Friday, April 13, 2012
• Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., completed enrollment of patients in a set of clinical trials to determine the usefulness of oxidation reduction potential in hospital readmission prediction, prevention and reduction in a group of patients presenting to the emergency department with chest pain. Readmission of Medicare and Medicaid patients within 30 days of discharge costs $17 billion annually.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription